Alpha Profiles · Company Profile

Abivax S.A.

https://registry.alpha.ac/companies/abivax-s-a

Entity: Public listing published
Primary listing: OTC: AAVXF
Verification: Partially verified
Last reviewed: 2026-09-05T21:41:36.362943+00:00

Overview

Abivax S.A., a French biopharmaceutical firm, specializes in the discovery and enhancement of pharmaceutical treatments targeting inflammatory conditions, infectious illnesses, and various forms of cancer. The company's flagship compound, ABX464, is currently undergoing Phase IIb clinical evaluations for ulcerative colitis, Crohn's disease, and COVID-19. It is also being assessed in Phase IIa trials for rheumatoid arthritis, and has successfully concluded Phase IIa studies demonstrating viral re

Canonical AEGIS identity graph

Executive leadership

Current, confirmed roles are shown only when both the person Profile and supporting source record satisfy the public projection boundary. A missing role is not evidence that it does not exist.

Executive team

3 public records

Didier Blondel

Executive Vice President, Chief Financial Officer and Board Secretary

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC 20-F 0001956827-26-000012Mar 23, 2026

Fabio Cataldi

Chief Medical Officer

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC 20-F 0001956827-26-000012Mar 23, 2026

Marc de Garidel

Chief Executive Officer and Director

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC 20-F 0001956827-26-000012Mar 23, 2026

Governance leadership

Boards & Committees

Board and committee assignments appear only when the canonical public projection retains a current role and supporting source. Unpublished records are not interpreted as absence.

Record as of Sep 5, 2026. Chair, executive office, Lead Independent Director and committee appointments retain their separate source roles. A complete board composition denominator and committee charters are not established by a partial roster.